September 11, 2017

pSivida to Present at Rodman & Renshaw Annual Global Investment Conference

WATERTOWN, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that Nancy Lurker, President and Chief Executive Officer, will be presenting at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 12, 2017 at 10:50 am (ET) at the Lotte New York Palace in New York, NY.

A live audio and/or webcast and subsequent archived replay of pSivida's presentations may be accessed via the Investors section of the Company's website under "Resources - Events & Presentations" at www.psivida.com. The replay will be available for 90 days after the event.

About pSivida Corp.

pSivida Corp. (www.psivida.com), headquartered in Watertown, MA, is a leader in the development of sustained release drug products for treating eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN®, a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold directly in the U.S. and three EU countries. Retisert ®, an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. pSivida's lead product candidate, Durasert micro-insert for posterior segment uveitis, is being independently developed. Two pivotal Phase 3 studies with Durasert achieved their primary efficacy endpoint at six months of follow-up with statistical significance, and the Company plans to file an NDA by the end of calendar 2017. pSivida's pre-clinical development program is focused on using its core platform technology Durasert™ to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis and other diseases. To learn more about pSivida, please visit www.psivida.com and connect on Twitter, LinkedIn, Facebook and Google+.

Contact:

EVC Group

Michael Polyviou/Doug Sherk - Investors
mpolyviou@evcgroup.comdsherk@evcgroup.com
212.850.6020; 646-445-4800

Thomas Gibson - Media
tom@tomgibsoncommunications.com
201-476-0322

Primary Logo

Source: pSivida Corp

News Provided by Acquire Media


Close window | Back to top

Copyright 2017 pSivida Corp.